Competing Risks for Recurrence After Nephron-Sparing Treatment in Renal Cell Carcinoma
Overview
In a population-based cohort of 2751 localized nonmetastatic renal cell carcinoma (nmRCC) patients treated with partial nephrectomy (PN) or ablative therapy (AT), local recurrence (LR) occurred in 4.0% and distant metastatic recurrence (DMR) in 3.9% over a mean follow-up of 4.8 years. AT-treated patients were older, had smaller tumors, and longer treatment wait times compared to PN-treated patients.
Background
Nephron-sparing approaches such as partial nephrectomy and ablative therapy are standard treatments for localized nonmetastatic renal cell carcinoma. Both treatments carry risks of local and distant recurrence, influenced by tumor size, multifocality, and invasion characteristics. Local recurrence rates after ablative therapy have been reported around 14%, whereas partial nephrectomy shows approximately 3%. The optimal salvage treatment after recurrence remains unclear, and comparative effectiveness of AT versus PN regarding recurrence and mortality has not been definitively established.
Data Highlights
Characteristic
AT-treated (n=429)
PN-treated (n=2322)
P-value
Mean age (years)
69.3 (11.1)
63.0 (11.6)
<0.001
Mean tumor size (mm)
27.5 (12.7)
33.7 (16.8)
<0.001
Incidental finding (%)
87.2%
79.8%
0.004
Mean waiting time to treatment (days)
208 (206)
125 (135)
<0.001
Local recurrence (LR)
4.0% overall
4.0% overall
Not specified
Distant metastatic recurrence (DMR)
3.9% overall
3.9% overall
Not specified
Death without LR/DMR
7.5% overall
7.5% overall
Not specified
Key Findings
Local recurrence occurred in 4.0% and distant metastatic recurrence in 3.9% of nmRCC tumors after nephron-sparing treatment.
AT-treated patients were significantly older and had smaller tumors compared to PN-treated patients.
Patients receiving AT experienced longer waiting times from diagnosis to treatment than those receiving PN.
Incidental tumor findings were more frequent in the AT group than in the PN group.
After recurrence, mortality was higher in patients with distant metastatic recurrence (51.9%) compared to local recurrence (21.6%).
Follow-up averaged 4.8 years, with recurrence typically developing within 20–36 months post-treatment.
Clinical Implications
Clinicians should consider patient age, tumor size, and timing when selecting between ablative therapy and partial nephrectomy for nmRCC. The relatively low local recurrence rates after both treatments support their use in nephron-sparing management. Close surveillance within the first 3 years post-treatment is critical due to the timing of most recurrences. Treatment decisions should also weigh the higher mortality associated with distant metastatic recurrence.
Conclusion
This large population-based study demonstrates comparable local and distant recurrence rates following nephron-sparing treatments in nmRCC, with patient and tumor characteristics differing between AT and PN groups. These findings inform risk stratification and follow-up strategies to optimize patient outcomes.
References
National Swedish Kidney Cancer Register (NSKCR) -- Data source 2005-2023
TNM 2017 Classification System -- Tumor staging reference
2016 WHO Classification -- Histopathological classification reference
